Karteikarten
Biochem 2

Karten in diesem Stapel (150)
- 1diagram to demonstrate the role of HMGCoA reductase and the action of statins

- 2name treatments for hyper lipidaemia- lifestyle - everyone
- patients at high risk- those with clinical disease in any vascular bed (cerebral, coronary, peripheral) should be given secondary prevention
-primary prevention to those with genetic hyperlipiademia/ high calculated CHD risk/ diabetes and age > 40 - 3what association has been noted , in JAMA cardiology 2017, relating to intensity of statin use and one year mortality meta-analyses have shown that increasing beyond certain intensity may not yield net benefitincreased intensity decreases one year mortality

- 4how might we analyse atheroma regression with treatments?- intravascular ultrasound

- 5look at this in your own time

- 6how do hepatocytes clear LDL?- LDL attaches to LDLR on hepatocyte membrane
- endocytosis of particle
- coated in clarithrin ( vesicle is coated)
- transported as an endosome
- lysozyme break-down into lysosome
- synthesis of LDLR by nucleus
- LDLR recycled by endosome - 7shown

- 8how then, does PCSK9 work?- is produced in the nucleus of the hepatocyte (PCSK9 gene)
- attaches to LDL- LDLR complex
- prevents LDLR recycle at endosome-> therefore less LDLR at the membrane
-therefore increased circulating LDL not being metabolised - 9image

- 10genetic studies have shown loss of function mutations of the PCSK9 to do what to CHD risk?- reduced risk
- PCSK9 cannot prevent LDLR recycle - therefore more LDL uptaken and metabolised
data demonstrated in black subjects - 11how then, might we utilise this for our benefit?- mimic the loss of function alleles by producing Mabs against PCSK9
more LDLR, less LDL
- EVOLOCUMAB a great example
'vaccine against PCSK9 lowers cholesterol in mice" - 12give some side-effects of statins- rhabdomyolysis, myalgia - don't use statins if symptoms exist (may be look at CK)
- liver- LFTs once per month according to NICE- ALT 2-3x higher than normal common and acceptable. Review if >3 x greater- make sure you know statins not always the cause
- diabetes- risk increased by 9%- earlier presentation/ those who wouldn't have gotten it
CVD benefit outweigh the risks - 13what are the target cholesterol levels - LDL? - Non-HDL?- <4
- LDL <2
Non-HDL <2.5 - 14how much protein exists in the serum in total ?- 60-80 g/L total serum protein
albumin makes up a large bulk- 35-50 g/L
-globulins 22-36g/L - 15name some functions of serum proteins- transport
-immunity
- oncotic pressure
- hormones
- clotting
- enzymes
- lipoproteins - 16name some lab tests used to measure the quantity of serum proteinalbumin- LFT profile and bone profile
total protein- LFT profile
GLOBULINS= TP- albumin (found in LFT profile)
can get specific protein: CRP, haptoglobin, caeruloplasmin (copper carriage-Wilsons?)
- complement, transferrin, beta-2-microglobulin
serum protein electrophoresis as a diagnostic test - 17describe albumin- synthesised by the liver
- half life of approximately 20 days
- serum concentration dependent on: synthesis, breakdown, loss and fluid status - 18what are the main functions of albumin?- for transport
- provides oncotic pressure - 19name causes of low albumin- reduced synthesis
- increased breakdown
- increased losses- renal
- dilution (including artefact)
- redistribution - 20name causes of high albumin - these are rare- standing
- dehydration
- venous stasis - 21hypoalbuminaemia caused by reduced synthesis is caused how?- chronic liver disease- liver produces albumin until 90-95% damage
- malnutrition and malabsorption- reduced supply of AA from GIT to liver - 22hypoalbuminaemia caused by increased catabolism is caused how?- severe illnesses
e.g. : sepsis, inflammation, trauma, malignancy
related to a poor prognosis (esp. malignancy) - 23hypoalbuminaemia caused by increased excess losses is caused how?- renal - nephrotic syndrome: proteinuria >3g/24hr
- results in low albumin plus oedema (oncotic pressure changes),
- dyslipidaemia, viscosity and renal impairment other causes
- GI- protein losing enteropathy
Skin- Burns, Psoriasis - 24diagram to explain why absence of a colloid pressure from albumin results in oedema. Not able to provide adequate pressure for fluid in extravascular compartment to reabsorb into distal capillary and so is left in interstitium

- 25hypoalbuminaemia caused by haemodilution excess losses is caused how?iatrogenically- excess fluid
- oedema- CCF, CLD
- pregnancy
- sample contamination - 26case of a 57 year old male with advanced alcoholic liver disease - has a microcytic anaemia key to look into history

- 2778 year old woman with SOB/infected leg ulcers - CRP suggests that the infection not to blame - - Hb low- due to dilution - would need other tests to confirm CCF- but key is to know that reduced Hb could be suggestive of a dilutional hypoalb

- 28describe redistribution as a cause of hypoalbuminaemia- common cause of acute change
- redistribution from plasma to interstitial
- increased capillary permeability (sepsis, inflammation, response to trauma)
- recumbency- small but significant changes - 2956 year old acute infective pancreatitis- albumin low (redistribution due to sepsis)

- 30describe the consequences of hypoalbuminaemia- reduced oncotic pressure - oedema
- reduced binding capacity a) transport b) potential for increased drug activity (less bound- more bioavailability) - 31describe oncotic pressure fully- osmotic pressure due to colloids (proteins)
- opposes hydrostatic pressure
- albumin major component
- acts to hold fluid within the circulating volume - 32diagram

- 33how does this progress to oedema ?- fluid leaks out of capillaries into the interstitium
- 34describe how hypoalbuminaemia causes changes to calcium levels- albumin binds calcium- around 50% - not physiologically active
- physiologically active calcium is free or ionised
- free calcium homeostasis is tightly controlled
- hypoalbuminaemia reduces total calcium but not free calcium
- lab needs to adjust for this pseudohypocalcaemia - 35example of how we adjust for albumin

- 36how might drugs be affected by hypoalbumaenia ?- drugs compete for albumin binding sites
- no biological feedback
- risk of toxicity at apparently normal drug levels in the presence of hypoalbuminaemia
- might necessitate the use of an adjusted drug level - 37how might we simply measure proteinuria ?- dipstick
- 38quantify normal proteinuria- normal urine total protein < 150mg/24hr
- normal albumin urine <30 mg/24hr - 39to what sensitivity can protein dip-sticks measure albumin?- albumin > 300mg/L
not very - 40describe simple limitations of urine dipsticks- bacterial contamination
- disinfectant
- very concentrated sample
- haematuria
- bodily secretions
- errors in reading strips - 41describe the albumin:creatinine ratio (ACR) and what is is used for- screening tool for renal disease etc
- is a spot urine test in the early morning (fresh in the morning)
- used as a marker of renal disease and a marker for CVD morbidity and mortality
normal ACR <3g/mol - 42an ACR of 3- 30g/mol is clinically what?- microalbuminaemia
- 43an ACR of 30- 70g/mol is clinically what?proteinuria
- 44an ACR of 70-250g/mol is clinically what?proteinuria
- 45an ACR of >250g/mol is clinically what?nephrotic
- 46table in summary

- 47name the four causes of proteinuria- glomerular
- tubular
- post-renal
- overflow - 48describe the glomerular cause to proteinuria- most common pathological cause
- increased permeability of the BASEMENT MEMBRANE
- nephrotic syndrome - >3g/24hr, v low serum alb, most commonly immunologically mediated GLOMERULONEPHRITIS
- can happen transiently through illness or exercise - 49name post renal causes of proteinuria- urinary tract infection
- semen
pus
blood
contamination
- post-renal tumour (urothelial?) - 50describe overflow as a cause of proteinuriaincreased plasma concentration of protein
- filtered load exceeds reabsorptive capacity - 51describe tubular causes of proteinuria- impaired reabsorption of protein (back into blood, from the tubules)
- causes: heavy metals, nephrotoxic drugs (NSAIDs etc- find more), chronic pyelonephritis, inherited syndromes such as fanconi syndrome - inadequate reabsorption at the proximal nephron - 52how might protein in fluid be useful in determining the type of fluid?- transudates exist with LOW PROTEIN and are a result of filtration across the capillary endothelium (oncotic pressure)
- exudates are fluids with HIGH PROTEIN and result from inflammatory processes that increase permeability
therefore differentiate the cause - 53how do we work out if the fluid is exudate or transudate?- by measuring albumin in the serum and in the fluid
- Light et al. 1972.
- fluid albumin:serum albumin > 0.5 THEN THE FLUID IS AN EXUDATE - 54what is CSF?- cerebrospinal fluid
- is an ultra filtrate of plasma
normally has low protein content (0.1-0.4 g/L) - 55elevated protein in the CSF could be due to?- may be pathological-
infection
chronic inflammation
blockage in spinal canal- tumour, fracture
- contamination from blood is common in sampling (LP)- traumatic tap/ SAH - 56a finding of hypergammaglobulinaemia is found to be poly/mono clonal how?- serum protein electrophoresis
- polyclonal - inflammation, infection, autoimmune disease, CLD
- mono-clonal- stem from an identical immune cell - 57name causes of a monoclonal hypergammaglobulinaemia- multiple myeloma- stem from a single immune cell
- Waldenström's macroglobulinaemia
- MGUS
- other b-cell malignancies - 58natural immunity refers to ?- the acute phase response
- 59name +ve acute phase proteins- CRP
-ferritin
- alpha-1-antitrypsin
- caeruloplasmin
- fibrinogen
- haptoglobin
- serum amyloid A - 60name -ve acute phase proteins- albumin
- transferrin - 61describe CRP as a marker of inflammation- NON-SPECIFIC, very sensitive acute phase marker of inflammation
- rise after 6-12 hours
peak at 48 hours
- 10000x increase
- half life of around 19 hours- rapid clearance - 62discuss CRP in viral/bacterial infection- normal CRP does not rule out inflammation- not specific
bacterial infection >40mg/L usually vs >300mg/L in sepsis
- viral infection- only minor elevation
- fall approx. 50% in 24 hours if antibiotics successful - 63in what cases then, should we use CRP?- detecting infection- BACTERIAL/ immunosuppression
- response to treatment
- connective tissue disease (NOT SLE- ESR)
- IBD
- prognosis e.g. acute pancreatitis
- cardiovascular risk (high sensitivity CRP) - 64describe alpha-1-antitrypsin- inhibitor of neutrophil elastase
- normally controls proteolytic enzymes from macrophages
- deficiency autosomal co-dominant
- homozygotes 1/4000
- linked with early onset EMPHYSEMA and CLD - 65describe haptoglobin- binds free Hb released from intravascular haemolytic
- taken up by reticuloendothelial system
prevents loss of iron
- low in haemolytic anaemia (sickle cell disease) but also CLD, mets, sepsis - 66describe caeruloplasmin- functions to oxidoreductase and iron transport
- copper carrying capacity
- low in Wilson's disease
- increased in acute phase
and in pregnancy, OCP - 67quick definition of metabolism- all chemical reactions taking place in the body which generate transfer of use energy
- 68describe inherited metabolic disorders (IMD)inherited genetic abnormalities
- absence or malfunction of an enzyme system
- individually rare but collectively make up 1in 3-4000 births - 69what must you remember about IMDs?- they are diverse in presentation and often multisystem
- 70describe the pathophysiology of IMDs

- 71describe how the pathophysiology may cause symptoms in IMD- accumulation of substrate
- deficient product
- secondary metabolic phenomena - 72what is the incidence of phenylketonuria ?- 1 in 10,000
- 73what mutations are responsible for phenylketonuria ?- to the phenylalanine hydroxylase gene
- leads to absent or reduced enzymatic activity or impaired binding to cofactor BH4 - 74how do we diagnose phenylketonuria?- seeing increased plasma phenylalanine (build up of substrate)
- seeing reduced tyrosine (product) - 75how might this influence the person affected by PKU?- neurotoxicity from PA
- impaired neurotransmitter synthesis
- developmental/mental problems, seizures and behavioural problems
mental retardation - 76what treatment exists for phenylketonuria?- low PA diet (reduces neurotoxicity)
- supplements (tyrosine)
prognosis is good in this instance - 77chemical schematic of PKU

- 78how might we classify IMDs?- 1. disorders involving complex molecules
2. intoxication
3. energy insufficiency - 79describe the typical IMD that is due to presence of complex molecules- permanent
- progressive
- independent of intercurrent illnesses
-unrelated to food intake - 80what is the pathophysiology of this class (complex molecules)?- cellular organelles involved
- diseases that disturb the synthesis or catabolism of complex molecules - 81give examples of IMDs involving complex molecules- lysosomal storage disorders
- peroxismal disorders - x-linked adrenoleukodystrophy, Zellwegers
- congenital disorders of glycosylation - 82describe a presentation of a patient with a lysosomal storage disorder- repeated URTI
- dysmorphism
- developmental delay
- behavioural problems such as aggressive behaviour
- enlarged abdomen - 83what might you find on examination in a patient with a lysosomal storage disorder?- macrocephaly
- course facial features
- kyphosis
- hepatosplenomegaly
- claw hands
- umbilical hernia - 84typical appearance of a patient with lysosomal storage disorder findings consistent with a mucopolysaccharidosis

- 85describe the function of a lysosome- is a cell recycling centre
- 40 now identified - 86how do lysosomal storage disorders work?- accumulation of partially degraded substances
- within the lysosome
- leads to disturbed cell homeostasis and early cell death - 87which cells are most likely to become damaged in a lysosome storage disorder?- ones with low-turnovers- neurons
- or rich in lysosomes- such as white cells - 88list clinical features of a lysosome storage disorder- 3-6 months of age
-neurological symptoms
- hepatosplenomegaly
- resp/ cardiac problems
might be bony abnormality - 89what is the natural course of LSD?- slow progression to life- threatening multi-organ disease
- 90how do we classify LSDs?by the storage material affected
e.g. mucopolysaccharidosis oligosaccharidoses, sphingolipidosis - 91what material accumulates in mucopolysaccharidosis?- glucosaminoglycans
examples of conditions- Hurler, Scheie, Hunter, Sanfilipo - 92what material accumulates in oligosaccharidoses?oligosaccharides
- fucosidosis
mannosidosis
sialidosis
schindlers disease - 93table to summarise

- 94what investigation findings might be found in a patient with a mucopolysaccharidosis (LSD)- haematology/biochem normal
- urine MPS gives positive glucosaminoglycans
increased dermatan sulphate and heparan sulphate - 95which cells might need analysing in the case of mucopolysaccharidosis?- white cells
- 96give treatment options for LSD- supportive and palliative care
- ENZYME replacement therapy
- bone marrow transplantation
- substrate reduction therapy
- chaperone therapy/gene therapy - 97name an enzyme replacement drug used in LSD- elaprase
- 98name members of the MDT for LSD- paeds, cardiac, ortho, ent, neuro, psych, physio
- 99what is the general consensus on enzyme replacement therapy for LSDseems to largely improve symptoms and there is improved quality of life
-
- long term unsure - 100Mucopolysaccharidosis (MPS) leads to the abnormal build up of?heparan sulphate
- dermatan sulphate
- keratan sulphate = - 101define an intoxication IMD- symptoms due to acute or progressive intoxication from the accumulation of toxic compounds proximal to a metabolic block
- 102what kind of presentations can occur with an intoxication IMD?- acute- vomiting, lethargy, coma, liver failure
chronic- progressive developmental delay, cardiomyopathy - 103give examples of intoxication IMDs- urea cycle defects
-metal metabolism disorders such as Wilson's disease
-PKU, tyrosinaemia- aminoacidurias
- organic acidurias- methylmalonic aciduria
- sugar intolerance (galactosaemia) - 104give a typical presentation for a person with a urea cycle defect- infant
- fitting/seizures
very high NH3 (ammonia)- - 105how is ammonia produced ?- catabolism of amino acids
- 106how can we define hyperammonaemia?- premature neonate NH3 > 150 umol/L
-term neonate > 100 umol/L
-infan, child and adult >40 umol/L - 107give symptoms of hyperammonaemia- acute tachypnoea
- lethargy
- vomiting convulsions
- encephalopathy
need to promptly investigate to avoid irreversible neurological damage - 108ammonia detoxification- learn this really well

- 109what is the commonest inherited defect of the urea cycle ?- OTC deficiency - refer to urea cycle
- 110name other IMDs that might cause an increased ammonia- organic acidurias - e.g. methylmalonic acuduria
- fatty acid oxidation defects
- hyperornithinaemia, hyperammonaemia, homocitrillinuaemia (HHH syndrome) - 111case from lecture

- 112these results from the case are consistent with which urea cycle defect?- carbamyl phosphate synthase deficiency (CPS-1)
- reduced citrilline production at the same time as raised ammonia - less conversion from NH3 to cit
- 113how would we acutely manage this patient ?- want to reduce intoxication by NH3- therefore stop protein intake
- high calorie infusion (glucose) to prevent catabolism (breakdown of protein)
- arginine - to drive urea cycle
- promote ammonia removal - sodium benzoate/pheynlbutyrate / haemofiltration if NH3 >300 umol/L - 114what management should be given long-term for this patient? remember that even after this significant developmental delay will be witnessed- referred to paediatric metabolic clinic for long-term follow up
- low protein diet
- benzoate and phenylbutryate
-arginine (drive) and citrulline
- emergency regime to avoid catabolism during intercurrent illness - 115what sites are used for the urea cycle?-liver- mainly
kidney- lesser extent
- this is in the mitochondria of the respective organs - 116what then, might be the natural course for a patient with a urea cycle deficiency ?- liver transplant
- 117define IMDs that cause impaired energy metabolism- symptoms due to deficiency in liver, metabolism, myocardium and muscle/brain
- 118give common symptoms of impaired energy metabolism IMDs- hypoglycaemia
- hyperlactiacidaemia
- hypotonia
- myopathy
- cardiomyopathy
-SUDIs- sudden unexpected death in infancy - 119give examples of the above- fatty acid oxidation defects
- glygenoses
- gluconeogenesis defects
- mitochondrial respiratory chain disorders - 120history of case 3

- 121results from investigations note hypoglycaemia raised ALT- related to liver damage

- 122how does the body respond to fasting?- through glycogenolysis / gluconeogenesis- glycogen break down in the muscle/glucose production in the liver from fatty acids and lactate
- through reduced peripheral glucose utilisation - namely by utilising other energy substrates such as fatty acids and ketones (oxidation) - 123—


- 124what blood glucose level defines a hypoglycaemia ?- <= 2.6mmol/L
- 125how may a neonate/infant present in the case of hypoglycaemia?- irritability
- somnolence- sleepiness/drowsiness
- tachypnoea
- hypothermia
- apnoea
- hypotonia
- seizures - 126how might older infants /children/adults present with hypoglycaemia ?- sweating
-apathy
- nausea
- headaches
- unusual behaviour
- seizures
- coma - 127give metabolic causes of hypoglycaemia- disorders of fatty acid oxidation - production of acylcarnitines such as octanoylcarnitine
- disorders of carbohydrate metabolism
- disorders of organic metabolism
- disorders of gluconeogenesis - 128urine organic acids such as ketones and a blood spot acylcarnitines is consistent with a diagnosis of?- medium-chain acyl COA dehydrogenase deficiency (MCADD)
- 129at what age does a case of MCADD tend to present?- usually 4 months to 3 years
- 130discuss MCADD- incidence of 1:8000
- metabolic crisis precipitated by fasting, illness, operations
- first crisis fatal in up to 25%
- occasionally asymptomatic - 131how then, is MCADD diagnosed?- organic acids
-acylcarnitines- increased octonoyl carnitine
-mutation analysis - common mutation = c.985A>G (K329E) - 132describe the acute management of MCADD- acute - high dose glucose IV +- insulin
- IV cartinine - 133describe the chronic management of MCADD- avoid fasting (avoidance of fat breakdown)
- diet low in fat and high in carb (utilising glucose instead of fat)
- emergency regime
- oral carnitine if deficient - 134case 3 summary of management

- 135when should you consider IMD?- in any child with: neurological deterioration/metabolic acidosis/hypoglycaemia/hypotonia/cardiomyopathy/liver dysfunction/dysmorphism/SUDI
- 136what blood tests would be performed if suspected inborn errors in metabolism are suspected?- glucose
- ammonia
- free fatty acids and 3 hydroxybutyrate
- blood gases
-lactate
- amino acids
- acylcarnitines
-LFTs (deranged?)
- FBC - 137what specific urine test would be useful for diagnosing IEM?- reducing substances
- ketones
- organic acids
- amino acids - 138name specific diagnostic tests for IEM- mucopolysaccharide test/screen
- very long chain fatty acids- for peroxisomal disorders
- CSF analysis (lactate respiratory chain disorders) - 139name non biochemical tests for the diagnosis of IEM- neuro-imaging (MRI peroxisomal disorders- white matter changes)
- ophthalmology assessment- cataracts galactosaemia - 140name confirmatory tests for the diagnosis of IEM- functional studies
- enzyme studies
- mutation analysis - 141name family tests for IEM- sibling testing
- prenatal diagnosis
newborn screening - 142slide - important to know these screening below

- 143—


- 144from when were newborn blood sport screening tests available for things like sickle, CF and MCADD?- 2004-2008
- 145name three amino acid disorders now screened for in the UK- PKU
- maple syrup urine disease
- homocystinuria - 146name the fatty acid oxidation disorder screened for in the UK- MCADD
- 147name the two organic acidurias now tested for/screened for in the UK- isovaleric acuduria
- Glutaric acuduria type 1 (GA1) - 148name the other three screened for diseases that make up the NHS England newborn blood spot screening programme (all of the above also involved)- Sickle cell
- CF
- congenital hypothyroidism - 149when is the newborn screened in these instances?- 5-8 days old blood spot
- 150—
Informationen
- Beschreibung
- Karteikarten am Biochem 2, erstellt von Alexander Wolff am 17/02/2018.
- Erstellt von
- Alexander Wolff
- Aufrufe
- 4
- Bewertung